We could not find any results for:
Make sure your spelling is correct or try broadening your search.
PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others. PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others.
PAVmed Provides Business Update and First Quarter 2024 Financial Results PR Newswire NEW YORK, May 13, 2024 Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission...
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results PR Newswire NEW YORK, May 13, 2024 Quarterly EsoGuard® test volume increased 10 percent Strengthened balance...
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall PR Newswire NEW YORK, May 9, 2024 EsophaCap device recalled due to recent publication of serious device...
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors PR Newswire NEW YORK, May 7, 2024 Final closing...
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024 PR Newswire NEW YORK, May 3, 2024 Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 3, 2024...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 PR Newswire NEW YORK, May 2, 2024 Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, May 2, 2024...
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal...
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute PR Newswire NEW...
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month PR Newswire NEW YORK, April 29, 2024 NEW YORK, April 29, 2024...
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire NEW YORK, April 8, 2024 NEW YORK, April 8, 2024 /PRNewswire/ -- Lucid...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.4085 | -17.3093220339 | 2.36 | 2.4199 | 1.85 | 45906 | 2.14245003 | CS |
4 | 0.0715 | 3.80319148936 | 1.88 | 2.4299 | 1.71 | 50449 | 2.08301632 | CS |
12 | 0.0715 | 3.80319148936 | 1.88 | 3.5 | 1.71 | 61972 | 2.34179242 | CS |
26 | -1.386 | -41.5280898876 | 3.3375 | 4.875 | 1.6 | 150049 | 3.35514798 | CS |
52 | -5.6985 | -74.4901960784 | 7.65 | 9 | 1.6 | 372274 | 5.01505457 | CS |
156 | -58.4985 | -96.7717121588 | 60.45 | 145.5 | 1.6 | 1037601 | 46.32489381 | CS |
260 | -16.4985 | -89.4227642276 | 18.45 | 145.5 | 1.6 | 1162634 | 46.88724701 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions